RVTY * Stock Overview Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Revvity, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Revvity Historical stock prices Current Share Price US$2,420.00 52 Week High US$2,595.00 52 Week Low US$2,343.00 Beta 1.09 1 Month Change 0% 3 Month Change n/a 1 Year Change -18.16% 3 Year Change n/a 5 Year Change n/a Change since IPO 35.26%
Recent News & Updates
Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Jan 31 Revvity, Inc. to Unveils New Phenologic.AI Software At SLAS2025 in San Diego, San Diego
Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024 Jan 16
Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025 Jan 13
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test Jan 10
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Nov 20 See more updates
Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Jan 31 Revvity, Inc. to Unveils New Phenologic.AI Software At SLAS2025 in San Diego, San Diego
Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024 Jan 16
Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025 Jan 13
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test Jan 10
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Nov 20 Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Nov 06
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Nov 05 Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025
Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 07
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Jul 30
Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024 Jul 26
Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 10
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Apr 30
Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024 Apr 27
Revvity Unveils A New Era of Automated Tuberculosis Testing Apr 24
Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Apr 05
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 Mar 21
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication Mar 20
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research Mar 15
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions Feb 13
Revvity Showcases Cutting-Edge Solutions at SLAS2024 Feb 02
Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024 Feb 01
Revvity, Inc., Annual General Meeting, Apr 23, 2024 Jan 27 Revvity, Inc. Announces Board Elections, Effective February 1, 2024
Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024 Jan 10
Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023 Jan 09
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Nov 29
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Nov 28
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Oct 31
Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024 Oct 27
Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 10
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure Sep 27
Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries Sep 06
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Aug 02
Revvity Declares Quarterly Dividend, Payable on November 10, 2023 Jul 23
Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 13
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research Jun 30
Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development Jun 13 Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.
Upcoming dividend of US$0.07 per share at 0.2% yield Apr 13
Insufficient new directors Apr 13
Insufficient new directors Apr 01
PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023 Feb 15
Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021) Feb 14
PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023 Jan 27
Upcoming dividend of US$0.07 per share Jan 12 PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023
Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021) Nov 16
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns Nov 15
Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021) Nov 09
PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 09
PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023 Oct 27 PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022
Upcoming dividend of US$0.07 per share Oct 13
PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing Sep 27
Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection Sep 23 PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022
Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021) Aug 02 New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.
PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors Jul 23
PerkinElmer, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 15
Upcoming dividend of US$0.07 per share Jul 14 PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Value-Defensive Index
Perkinelmer Introduces Next Generation, Automated Gas Chromatography Platform Jun 22
PerkinElmer Expands Food Safety Testing Portfolio with AOAC Certified Microbial Count Plates Jun 09
PerkinElmer, Inc. Launches BioQule NGS System to Automate Library Preparation Jun 07
First quarter 2022 earnings released: EPS: US$1.40 (vs US$3.39 in 1Q 2021) May 13
PerkinElmer, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022 May 04
Upcoming dividend of US$0.07 per share Apr 14
PerkinElmer, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 13
PerkinElmer, Inc. Expands in Vivo Instruments Portfolio with Hands-Free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System Apr 08
PerkinElmer, Inc. Introduces First Ready-To-Use HTRF and AlphaLISA Assay Kits for CHO HCP Impurities Detection and Quantification Apr 05
Perkinelmer, Inc. Launches ChemDraw V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft Powerpoint Reports Mar 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 03
PerkinElmer, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022 Feb 02
PerkinElmer, Inc. Declares Quarterly Dividend, Payable on May 13, 2022 Jan 28
PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021 Jan 12
PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country Channel Partner for Milk and Dairy Testing Solutions Dec 20
PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance Dec 09
PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management Nov 24
Third quarter 2021 earnings released: EPS US$1.11 (vs US$1.58 in 3Q 2020) Nov 04
Upcoming dividend of US$0.07 per share Oct 15
PerkinElmer, Inc. Receives U.S. Food and Drug Administration Emergency Use Authorization for PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 Assay Oct 09
PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins Aug 21
Second quarter 2021 earnings released: EPS US$2.19 (vs US$1.23 in 2Q 2020) Jul 28 Shareholder Returns RVTY * MX Life Sciences MX Market 7D 0% 0% 0% 1Y -18.2% 0% 0%
See full shareholder returns
Return vs Market: RVTY * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility Is RVTY *'s price volatile compared to industry and market? RVTY * volatility RVTY * Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: RVTY * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RVTY *'s volatility change over the past year.
About the Company Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
Show more Revvity, Inc. Fundamentals Summary How do Revvity's earnings and revenue compare to its market cap? RVTY * fundamental statistics Market cap Mex$278.82b Earnings (TTM ) Mex$6.00b Revenue (TTM ) Mex$51.35b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RVTY * income statement (TTM ) Revenue US$3.02b Cost of Revenue US$1.21b Gross Profit US$1.81b Other Expenses US$1.46b Earnings US$353.45m
Last Reported Earnings
Apr 02, 2023
Next Earnings Date
Aug 01, 2023
Earnings per share (EPS) 2.82 Gross Margin 59.86% Net Profit Margin 11.69% Debt/Equity Ratio 54.3%
How did RVTY * perform over the long term?
See historical performance and comparison Dividends
0.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/07/22 08:34 End of Day Share Price 2023/04/24 00:00 Earnings 2023/04/02 Annual Earnings 2023/01/01
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Revvity, Inc. is covered by 39 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Luke Sergott Barclays Charles Butler Barclays
Show 36 more analysts 
